Baltimore-For patients with total PSA levels in the range of 2.5 to 4.0 ng/mL, measuring the proportion of precursor forms of PSA (pPSA) relative to free PSA (fPSA) may significantly lower the number of unnecessary biopsies compared with measuring percent-free PSA (%fPSA) alone, a new study suggests.
EV/pembrolizumab under review in China for advanced urothelial carcinoma
March 28th 2024The sBLA is supported by findings from the phase 3 EV-302 trial, which showed that EV/pembrolizumab extended overall survival and progression-free survival vs platinum-based chemotherapy in patients with advanced urothelial carcinoma.
Potential code for prior authorizations on AMA CPT Editorial Panel meeting agenda
March 28th 2024"Good public and economic policy must align costs, benefits, and incentives; currently, all costs are incurred by physician practices, and all financial savings and benefits from prior authorization accrue to health insurance plans, leading to perverse incentives,” says Alex Shteynshlyuger, MD.